Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
Authors:
Top Cited Papers
- 15 December 2022
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 8 (2) , 169-178
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
This publication has 29 references indexed in Scilit:
- Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cmBMC Cancer, 2016
- Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomasStrahlentherapie und Onkologie, 2015
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyThe Lancet Oncology, 2015
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJournal of Hepatology, 2013
- Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2013
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2008
- Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinomaLiver International, 2005
- Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact SurvivalHepatology, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- A Confidence Interval for the Median Survival Time1982